Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

GLP-1 (endogenous; Exendin(9-39) Antagonist Probe)

MARKETED

GLP-1R agonist/antagonist (physiology)

1
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 1Very low evidence 0

GLP-1 (endogenous; Exendin(9-39) Antagonist Probe) is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
GLP-1 (endogenous; Exendin(9-39) Antagonist Probe) MARKETED
Appetite and food intake No change
Low evidence

Pharmacological GLP-1R blockade with exendin(9-39) only slightly modulated appetite during ad libitum eating and did NOT change food intake, fluid intake or meal...

Steinert RE et al., Am J Clin Nutr 2014;100(2):514-523 Source
Full findingPharmacological GLP-1R blockade with exendin(9-39) only slightly modulated appetite during ad libitum eating and did NOT change food intake, fluid intake or meal duration in healthy men, suggesting endogenous GLP-1 is a comparatively weak physiological satiation signal — distinct from the large effect of pharmacological agonism.
PopulationHealthy men, n=10 x2 studies
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Scope limitssmall sample (N~10)
Comparatorssaline/vehicle